DOCSLIB.ORG

137 Elsevier NARCOTIC DISCRIMINATION

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
137 Elsevier NARCOTIC DISCRIMINATION European Journal of Pharmacology, 105 (1984) 137-142 137 Elsevier NARCOTIC DISCRIMINATION IN PIGEONS: ANTAGONISM BY NALTREXONE SEYMORE HERLING *, RITA J. VALENTINO **, ROBERT E. SOLOMON *** and JAMES H. WOODS Departments of Pharmacology and Psychology, University of Michigan, Ann Arbor, Michigan 48109, U.S.A. and Clinical Institute, Addiction Research Foundation, Toronto, Ontario, Canada Received 27 June 1984, accepted 9 July 1984 S. HERLING, R.J. VALENTINO, R.E. SOLOMON and J.H. WOODS, Narcotic discrimination in pigeons." Antagonism by naltrexone, European J. Pharmacol. 105 (1984) 137-142. In pigeons trained to discriminate between morphine (10 mg/kg) and saline, both morphine and ethylketazocine produced dose-related morphine-appropriate responding. The maximum effect produced by meperidine, however, was only 60% of that produced by morphine or ethylketazocine. Naltrexone (0.1-1.0 mg/kg) produced dose-related shifts to the right in the dose-response curves for the discriminative stimulus and rate-decreasing effects of morphine and ethylketazocine without affecting the response produced by meperidine. Thus, in contrast to the effects observed in other species, morphine and ethylketazocine produce similar discriminative effects in the pigeon. In addition, the morphine-like discriminative effects and the rate-decreasing effects of meperidine in the pigeon are not mediated by the naltrexone-sensitive mechanisms which mediate these effects of morphine or ethylketazocine. Morphine Ethylketazocine Meperidine Drug discrimination Antagonism Pigeons 1. Introduction man, 1980; Schaefer and Holtzman, 1981). In the pigeon, however, morphine, ethylketazocine, and Several lines of evidence suggest that many of ketazocine appear to share discriminative stimulus the effects of ethylketazocine and other x-receptor effects, since each of these drugs produces dose-re- agonists in several species are mediated by a recep- lated drug-appropriate responding in pigeons tor that differs from that mediating the effects of trained to discriminate between either morphine or morphine (a /x-receptor agonist) (Woods et al., ethylketazocine and saline (Herling and Woods, 1978; Iwamoto and Martin, 1981; Wood, 1982). 1981). Results of drug discrimination studies are con- Additional evidence that the behavioral effects sistent with this concept (Herling and Woods, of morphine and ethylketazocine in certain species 1981). For example, in rats or squirrel monkeys are mediated by different mechanisms is derived trained to discriminate between morphine and from studies on the antagonism of these effects by saline, neither ketazocine nor ethylketazocine sub- naloxone or naltrexone. In rats, for example, the stitutes for morphine as a discriminative stimulus effects of ketazocine and ethylketazocine on sched- (Shannon and Holtzman, 1977; Teal and Holtz- ule-controlled responding are more difficult to antagonize by naltrexone than are similar effects * To whom all correspondence should be addressed: Addic- of morphine (Harris, 1980). More recently, Leander tion Research Foundation, 33 Russell Street, Toronto, (1982) has shown that the effects of phenazocine Ontario, Canada M5S 2S1. (a proposed /~ agonist) on schedule-controlled re- ** Present address: Department of Pharmacology, George sponding in the pigeon were also reversed by Washington University Medical Center, 2300 Eye Street considerably smaller doses of naloxone (0.01-1.0 NW, Washington, D.C. 20037, U.S.A. *** Present address: University of Iowa College of Medicine, mg/kg) than were comparable effects of either Iowa City, IA 52242, U.S.A. ethylketazocine or ketazocine. Thus, in contrast to 0014-2999/84/$03.00 © 1984 Elsevier Science Publishers B.V. 138 the discriminative effects of ethylketazocine and required to emit 20 consecutive responses on one ketazocine in the pigeon, which on the basis of of two keys to produce 4-s access to food. The key cross-generalization results were suggested to be on which responses produced food was determined mediated similarly to the discriminative effects of by the i.m. presession injection of either 10 mg/kg /~ agonists (Herling and Woods, 1981), the re- morphine (left key) or saline (right key). Re- sponse rate-decreasing effects of ethylketazocine sponses on the inappropriate key reset the re- and ketazocine in the pigeon appear to be media- sponse requirement on the appropriate key. Ses- ted differently than the rate-decreasing effects of/~ sions ended after 32 food deliveries or 1 h, agonists (Leander, 1982). whichever occurred first. Training sessions were The purpose of the present experiment was to conducted 6 days per week with morphine and compare the ability of the narcotic antagonist saline injections alternating from one session to naltrexone to antagonize the discriminative stimu- the next. lus and rate-decreasing effects of morphine and Once the training criteria were met (refer to ethylketazocine in the pigeon to determine if dif- Herling et al., 1980 for details), test sessions were ferent behavioral effects of these drugs are media- conducted with morphine, ethylketazocine, or ted differently. In addition, the ability of naltre- meperidine, alone or in combination with naltre- xone to antagonize the discriminative and rate-de- xone. During test sessions, 20 consecutive re- creasing effects of meperidine was determined. As sponses on either the morphine- or saline-ap- a discriminative stimulus, meperidine substitutes propriate key resulted in food delivery; in all other only partially for morphine in the pigeon (Herling respects, test sessions were identical to training et al., 1980), and whereas the response rate-in- sessions. creasing effects of lower doses of meperidine are Morphine sulfate (Mallinckrodt Chemical antagonized by naloxone, the response rate-de- Works, St. Louis, MO), meperidine hydrochloride creasing effects of higher doses of meperidine are (Sterling-Winthrop Research Institute, Rensselaer, not (Leander and McMillan, 1977). Thus, whether NY) and naltrexone hydrochloride (Endo Labora- the partial morphine-like discriminative effects of tories, Garden City, NY) were dissolved in 0.9% meperidine might be blocked by naltrexone was sterile saline. Ethylketazocine methane sulfonate assessed. (Sterling-Winthrop Research Institute) was dis- solved in sterile water to which a small amount of lactic acid was added; sodium hydroxide was used to adjust the pH above 3. All drugs were injected 2. Materials and methods i.m., usually in a volume of 1 ml/kg, 10 rain before the start of the session. When drug combi- The subjects were four White Carneaux pigeons nations were studied, naltrexone was injected into maintained at approximately 80% of free-feeding the breast muscle on one side of the animal, fol- weight. These pigeons had served as subjects in an lowed immediately by an injection of morphine, earlier morphine discrimination experiment (Her- ethylketazocine or meperidine into the breast ling et al., 1980). muscle on the opposite side. Experimental sessions were conducted in cham- The data for test sessions are presented as the bers that have been described in detail previously average number of responses throughout the ses- (Herling et al., 1980). Briefly, the inside front sion that were emitted on the morphine-ap- panel of each chamber contained two translucent propriate key, expressed as a percentage of the response keys that were transilluminated during total responses. The overall rate of responding on experimental sessions by red 7-W lights. Food the two keys was also recorded during each ses- (mixed grain) could be presented to the pigeon sion. The average rate of responding after drug through a rectangular opening located below the injection is expressed as a percentage of the previ- keys. During training sessions, each pigeon was ous saline control rates. 139 3. Results fect curves for the discriminative effects of morphine and ethylketazocine to the right (fig. 1, Morphine and ethylketazocine, when adminis- upper panels). The minimum doses of morphine tered alone, produced dose-related increases in the and ethylketazocine required to produce at least percentage of responses emitted on the morphine- 90% morphine-appropriate responding were shifted appropriate key (fig. 1, upper panels: closed to the right by 0.1 mg/kg of naltrexone approxi- circles). Morphine doses of 10 mg/kg and higher mately 6-fold and 19-fold, respectively. In the and ethylketazocine doses of 3 mg/kg and higher presence of 1.0 mg/kg of naltrexone, doses of resulted in greater than 90% morphine-appropriate morphine or ethylketazocine up to 100 mg/kg responding in each pigeon. Meperidine also pro- produced less than 55% morphine-appropriate re- duced dose-related morphine-appropriate respond- sponding. Naltrexone also shifted the dose-effect ing, but the average maximum effect, which oc- curves for the rate-decreasing effects of morphine curred at 5.6 mg/kg, was only 60% of the maxi- and ethylketazocine to the right (fig. 1, lower mum effect produced by morphine or ethyl- panels). The shifts in dose-effect curves for the ketazocine (fig. 2, upper panel: closed circles). All rate-decreasing effects of morphine and ethyl- three drugs produced dose-related decreases in the ketazocine were less pronounced than the shifts rate of responding (figs. 1 and 2, lower panels: for the discriminative effects of the drugs. Doses closed circles). The lowest doses of morphine, eth- of morphine and ethylketazocine required to pro- ylketazocine, and meperidine which produced duce a 50% decrease in response rate were shifted maximum morphine-appropriate responding, re- to the right by 0.1 mg/kg of naltrexone approxi- duced response rates by approximately 20, 30 and mately 1.5- and 4.0-fold, respectively. 50%, respectively. In contrast to the effects of morphine and eth- Naltrexone (0.1-1.0 mg/kg) shifted the dose-ef- ylketazocine, neither the discriminative stimulus , MORPHINE ETHYLKETAZOCINE bJ = ,0o 7 ~ 8016o om ~ 40 >- 2O ~-~ o I I I I I t I I I I I I I I ,,~ 120- 0 m ~ I00- "~n~ (,,) 80- ~,~ 60- ~z~ 40" 0 + 1.0 MG/KG NALTREXONE =~ 20- 'e O- I I I l I F ~) I L I ~',~ 32 ,~o o.I 0.3 i 3 i 32 ioo DOSE (mg/kg, i.m.) Fig.
Load more

Recommended publications
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Measures and CDS for Safer Opioid Prescribing: a Literature Review
    Measures and CDS for Safer Opioid Prescribing: A Literature Review Measures and CDS for Safer Opioid Prescribing: A Literature Review Executive Summary The U.S. opioid epidemic continues to pose significant challenges for patients, families, clinicians, and public health policy. Opioids are responsible for an estimated 315,000 deaths (from 1999 to 2016) and have caused 115 deaths per day.1 In 2017, the U.S. Department of Health and Human Services declared the opioid epidemic a public health crisis.2 The total economic burden of opioid abuse in the United States has been estimated to be $78.5 billion per year.3 Although providing care for chronic opioid users is important, equally vital are efforts to prevent so-called opioid-naïve patients (patients with no history of opioid use) from developing regular opioid use, misuse, or abuse. However, much remains unclear regarding what role clinician prescribing habits play and what duration or dose of opioids may safely be prescribed without promoting long-term use.4,5 In 2013, ECRI Institute convened the Partnership for Health IT Patient Safety, and its component, single-topic-focused workgroups followed. For this subject, the Electronic Health Record Association (EHRA): Measures and Clinical Decision Support (CDS) for Safer Opioid Prescribing workgroup included members from the Healthcare Information and Management Systems Society (HIMSS) EHRA and the Partnership team. The project was oriented towards exploring methods to enable a synergistic cycle of performance measurement and identifying electronic health record (EHR)/health information technology (IT)–enabled approaches to support healthcare organizations’ ability to assess and measure opioid prescribing.
    [Show full text]
  • Comparison Between Morphine and Morphine Plus Ketamine for Postoperative Pain Relief After Orthopaedic Surgery
    Ο University of Khartoum Faculty of Medicine Postgraduate Medical Studies Board Comparison between Morphine and Morphine plus Ketamine for postoperative pain relief after orthopaedic surgery By Dr. Sarah Mahmoud Nuri M.B.B.S, (University of Khartoum) A thesis submitted in partial fulfilment for the requirements of the degree of Clinical MD in anaesthesia & intensive care, May 2004 Supervisor Prof. Ali Ahmed Salama MBBS, DA, FFA Faculty of Medicine Neelain University To my mother ...... My grateful acknowledgement is made to Dr. Ali Ahmed Salama for his supervision, encouragement, and advice during the performance of this study. I'm also grateful to all orthopaedic registrars and house officers who helped me in collecting the data. I’m also grateful to Dr. Yassir Salih for his great help and support. I would like also to thank my family for their help and support. LIST OF ABBREVIATIONS CAMP Cyclic adenosine mono phosphate. PIP2 Phosphatidyl inositol di phosphate. IP3 Inositol tri phosphate. ADH Anti Diuretic Hormone. GF Glumerular Filtration. BP Blood Pressure. ECG Electro cadiogram. CBF Cerebral Blood Flow GI Gastro Intestinal CNS Central Nervous system ASA American Society of Anesthiologist VAS Visual analogue scale. NSAIDs Non steroidal anti infalammatory drugs. NMDA N-methyl- D- Aspartate GFR Glumerular filtration rate. EEG Electroencephalogram. ABSTRACT The aim of this study is detection of the efficacy of ketamine in low doses as a potent analgesic and it's ability to provide superior analgesia when added to morphine. It compared morphine with ketamine to morphine alone in Quasi experimental design of post surgical pain control . Also this study compared the incidence of morphine common side effects between the two groups.
    [Show full text]
  • Opioids Regulate Cgmp Formationin Cloned Neuroblastoma Cells
    Proc. NatL. Acad. Sci. USA Vol. 79, pp. 690-694, January 1982 Neurobiology Opioids regulate cGMP formation in cloned neuroblastoma cells (cyclic nucleotides/opiate receptor/desensitization) GERMAINE J. GWYNN AND ERMINIO COSTA* Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D.C. 20032 Communicated by Floyd E. Bloom, October 8, 1981 ABSTRACT Opioid agonists caused a rapid dose-related el- cumulation in rat striatal slices with characteristics that fulfill evation of the cGMP content of N4TG1 murine neuroblastoma the criteria for a specific narcotic action (6). In contrast, the cells. An excellent correlation was found between the rank order decrements in the cGMP content ofcerebellar tissue observed of potency of agonists in stimulating cGMP accumulation and in after morphine administration are probably indirect effects of displacing [3H]etorphine ([H]ETP) bound to intact cells. The nar- opioid receptor stimulation mediated by the modulation of y- cotic antagonists naloxone and diprenorphine failed to increase aminobutyric acid or acetylcholine collateral neuronal loops (7, cGMP content; moreover, in the presence of 5 ,IM naloxone, the 8). A functional role for cGMP in opioid action is further sug- EC50 of ETP increased from w9 nM to >1 ,uM. N4TG1 cells that had been incubated for 20 min with 0.32 ItM ETP and thoroughly gested by the pivotal role that calcium ions play both in regu- washed displayed a marked loss in sensitivity to subsequent ETP lating cGMP formation (for review, see refs. 9, 10) and in me- challenge. This desensitization was characterized by a 40-50% diating the acute and chronic effects ofopioids (for review, see decrease in maximal response and an increase in the apparent Ka refs.
    [Show full text]
  • '. Opiates Induce Long-Term Increases in Prodynorphin-Derived Peptide
    '. Nuunyn·Schm,cd(!bc'Q' G NauIIYII-Schrnicdcbcrg's Arch I'harlllacol (I<)X6) 33J :Jlil -3X6 Archives of Pharmacology Opiates induce long-term increases <!) Springcr-Vcrlag 1<)1(6 in prodynorphin-derived peptide levels in the guinea-pig myenteric plexus Riidi~cr Schull I , Katharina Mctlncr 1, Thomas Dandckar 1, and Christilln C,ramsch 1 I IIISlilul fiir Pharmakologie. Tllxikologie und Pharmazie. TieriirzllidlC Fakuiliil der Univcrsiliil Miinchcn. Ki.iniginslr. 16. D-liOOO Miinehcn 22. f-cderal Republic ofGcrmany 2 f)cparlrnenl of Ncurophamlacology. Max-l'lanck-lnslilul fUr Psychi'llric. Am Klopfcrspilz IXa. D-X033 Planegg-Marlinsried. Federal Republic of Germany Summary. The subcutaneous administration of a single dose during the state of morphine tolerance/dependence of an oriate agonist (levorphanol) or antagonist (naloxone) (Simantov and Snyder 1976). One investigation of the pe­ to guinea rigs results in an at least 3-fold elevation of ripheral nervous system revealed no changes in enkephalin dynorrhin and alpha-neoendorphin-immunoreactivity in concentrations in the myenteric plexus of the guinea-pig lhe longitudinal muscle myenteric rlexus preparation. The ileum upon chronic morphine exposure; however, eflccts arc time- and dose-dependent. significant elevations moderately increased levels of /I-cndorphin fragments were first' being observed 6 h after treatment and lasting for up observed (Opmeer et al. 19RO). to 24 h, Pretreatment levels of opioid pcptides were observed The data reported so far thus suggest that treatment of after 8 days, Combined injection of the narcotic agonist and animals with exogenous opioids may affect the concentra­ antagonist. at sufficiently high doses, resulted in an additive tions of some endogenous opioids but not of others.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 12/024482 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, ' February 2012 (09.02.2012) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 13/024,298 9 February 201 1 (09.02.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): QRX- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA LTD.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol
    Index AIDA, 495 Affinity labeling, analogs of (Cont.) cAMP, 409, 489 motphine,448 ATP, 409, 489 naltrexone, 449 [3H] ATP, 489 norlevotphanol,449 Absolute configuration normetazocine, 181 benzomotphans, 204 norpethidine, 232 levotphanol, 115 oripavine, 453 methadone and analogs, 316 oxymotphone, 449 motphine, 86 K-Agonists, 179,405,434 phenoperidine, 234 Aid in Interactive Drug Analysis, 495 piperazine derivatives, 399 [L-Ala2] dermotphin, 363 prodines and analogs, 272 [D-Ala, D-Leu] enkephalin (DADL), 68, 344 sinomenine, 28, 115 [D-Ala2 , Bugs] enkephalinamide, 347, 447 viminol, 400 [D-Ala2, Met'] enkephalinamide, 337, 346, Ac 61-91,360 371,489 Acetylcholine, 5, 407 [D-Ala2]leu-enkephalin, 344, 346, 348 Acetylcholine analogs, 186, 191 [D-Ala2] met-enkephalin, 348 l-Acetylcodeine, 32 [D-Ala2] enkephalins, 347 Acetylmethadols (a and (3) Alfentanil, 296 maintenance of addicts by a-isomer, 304, 309 (±)-I1(3-Alkylbenzomotphans, 167, 170 metabolism, 309 11(3-Alkylbenzomotphans, 204 N-allyl and N-CPM analogs, 310, 431 7-Alkylisomotphinans, 146 stereochemistry, 323 N-Alkylnorketobemidones, 431 synthesis, 309 N-Alkylnorpethidines, 233 X-ray crystallography, 327 N-Allylnormetazocine, 420 6-Acetylmotphine, receptor binding, 27 N-Allylnormotphine, 405 Acetylnormethadol, 323 N-Allylnorpethidine, 233 8(3-Acyldihydrocodeinones, 52 3-Allylprodines (a and (3), 256 14-Acyl-4,5-epoxymotphinans, 58 'H-NMR and stereochemistry, 256 7-Acylhydromotphones, 128 X-ray crystallography, 256 Addiction, 4 N-Allylnormetazocine, 420 Adenylate cyclase, 6, 409, 413, 424,
    [Show full text]
  • Symposium Iv. Discriminative Stimulus Effects
    Life Sciences, Vol. 28, pp. 1571-1584 Pergamon Press Printed in the U.S.A. MINI - SYMPOSIUM IV. DISCRIMINATIVE STIMULUS EFFECTS OF NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS Seymore Herling and James H. Woods Departments of Pharmacology and Psychology University of Michigan Ann Arbor, Michigan q8109 The different pharmacological syndromes produced by morphine and related drugs in the chronic spinal dog led Martin and his colleagues (1,2) to suggest that these drugs exert their agonist actions 0y interacting with three distinct receptors (~,K, and e). Morphine was hypothesized to be an agonist for the p receptor, ketazocine (ketocyclazocine) was an agonist for the K receptor, and SKF-10,0q7 was an agonist for the ~ receptor. The effects of these three drugs in the chronic spinal dog were reversed by the narcotic antagonist, naltrexone, indicating that the effects of these drugs are narcotic agonist effects (I). In additlon to the different effects of these narcotics in the non- dependent chronic spinal dog, the effects of morphine, ketazocine, and SKF-IO,047 in several other behavioral and physiological preparations are consistent with the concept of multiple receptors. For example, while ketazocine and ethylketazocine, like morphine, produce analgesia, these compounds, unlike morphine, do not suppress signs of narcotic abstinence in the morphine-dependent rhesus monkey or morphine-dependent chronic spinal dog (1-5). Further, the characteristics of ketazocine withdrawal and antagonist- precipitated abstinence syndromes, although similar to those of cyclazocine, are quailtativeiy different from those of morphine (1,2). In rhesus monkeys, ketazocine, ethylketazocine, and SKF-10,047 maintain lever pressing at rates comparable to or below those maintained by saline, and well below response rates maintained by codeine or morphine (5,6), suggesting that the former set of drugs have limited reinforcing effect.
    [Show full text]
  • Psychoactive Natural Products: Overview of Recent Developments
    12 Ann Ist Super Sanità 2014 | Vol. 50, No. 1: 12-27 DOI: 10.4415/ANN_14_01_04 Psychoactive natural products: overview of recent developments István Ujváry REVIEWS iKem BT, Budapest, Hungary AND Abstract Natural psychoactive substances have fascinated the curious mind of shamans, artists, Key words ARTICLES scholars and laymen since antiquity. During the twentieth century, the chemical com- • ethnopharmacology position of the most important psychoactive drugs, that is opium, cannabis, coca and • mode of action “magic mushrooms”, has been fully elucidated. The mode of action of the principal in- • natural products gredients has also been deciphered at the molecular level. In the past two decades, the • psychopharmacology RIGINAL use of herbal drugs, such as kava, kratom and Salvia divinorum, began to spread beyond • toxicology O their traditional geographical and cultural boundaries. The aim of the present paper is to briefly summarize recent findings on the psychopharmacology of the most prominent psychoactive natural products. Current knowledge on a few lesser-known drugs, includ- ing bufotenine, glaucine, kava, betel, pituri, lettuce opium and kanna is also reviewed. In addition, selected cases of alleged natural (or semi-natural) products are also mentioned. O, mickle is the powerful grace that lies In herbs, plants, stones, and their true qualities William Shakespeare (Romeo and Juliet) INTRODUCTION Historical background of psychoactive natural During the past 200 years, there has been major pro- products research gress in our understanding of the composition and ef- The biochemical machinery of an organism generates fects of many psychoactive natural products, particular- many structurally related chemicals (Nature’s “combinato- ly those that have therapeutic uses.
    [Show full text]